Novartis AG
ianalumab
Sjögren’s disease
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for ianalumab in Sjögren’s disease are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 14h ago
“following the first global Phase III trials to demonstrate a statistically significant reduction in disease activity.”